Last reviewed · How we verify

Lundbeck LLC — Portfolio Competitive Intelligence Brief

Lundbeck LLC pipeline: 1 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Sabril® Sabril® marketed GABA transaminase inhibitor GABA transaminase (ABAT) Neurology
Clobazam Medium Dose Clobazam Medium Dose phase 3 Benzodiazepine GABA-A receptor Neurology
Clobazam High Dose Clobazam High Dose phase 3 Benzodiazepine GABA-A receptor Neurology
Clobazam Low Dose Clobazam Low Dose phase 3 Benzodiazepine anticonvulsant GABA-A receptor Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ajenat Pharms · 1 shared drug class
  2. Assaf-Harofeh Medical Center · 1 shared drug class
  3. Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 shared drug class
  4. B.P. Koirala Institute of Health Sciences · 1 shared drug class
  5. Bausch Health · 1 shared drug class
  6. Centro Medico Nacional La Raza, IMSS · 1 shared drug class
  7. Chang Gung Memorial Hospital · 1 shared drug class
  8. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lundbeck LLC:

Cite this brief

Drug Landscape (2026). Lundbeck LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lundbeck-llc. Accessed 2026-05-14.

Related